Sareum (LON:SAR) Shares Down 8.5% – Here’s What Happened

by · The Markets Daily

Sareum Holdings plc (LON:SAR – Get Free Report) shares dropped 8.5% on Monday . The stock traded as low as GBX 22 and last traded at GBX 23. Approximately 800,784 shares were traded during trading, an increase of 240% from the average daily volume of 235,736 shares. The stock had previously closed at GBX 25.14.

Sareum Price Performance

The company’s 50-day moving average price is GBX 19.18 and its two-hundred day moving average price is GBX 17.07. The company has a market capitalization of £31.75 million, a price-to-earnings ratio of -5.90 and a beta of -1.08.

Sareum (LON:SAR – Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The company reported GBX (1.20) earnings per share for the quarter. On average, equities research analysts expect that Sareum Holdings plc will post -3.8 EPS for the current fiscal year.

About Sareum

(Get Free Report)

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

Featured Articles